Study on the Effects of 12-Week ETAS450mg Supplement on Thinking, Mood, and Brain Health in Adults Aged 60 to 80

What this Trial Is About

Researchers are investigating the long-term effects of ETAS450mg daily on cognitive, emotional, and brain health in healthy adults aged 60 to 80 years who have mild to moderate subjective cognitive complaints. This study uses a double-blind, randomized, placebo-controlled design to evaluate changes in cognitive function, mood, inflammation, metabolism, and body measurements over a 12-week period. Participants are randomly assigned to one of two groups one receiving ETAS450mg capsules daily and the other receiving matched placebo capsules for 12 weeks. Outcome measures are taken before and after the intervention and include assessments of overall cognitive performance, executive function, language and memory, depression, anxiety, sleep quality, gastrointestinal symptoms, blood pressure, body measurements, and brain structure and function using MRI techniques. Additionally, a subset of participants will collect stool samples at home to analyze gut microbiome diversity and composition at baseline and after 12 weeks. Throughout the study, participants will undergo various tests and questionnaires to monitor cognitive, emotional, and physical health, including the Montreal Cognitive Assessment, fMRI, magnetic resonance spectroscopy, sleep quality indices, and more. Researchers will also track anthropometric data and blood pressure. The study aims to understand how chronic ETAS450mg supplementation influences these measures in older adults over the 12-week intervention period.

ETASCAN Project: ETAS Project 2